Once daily oral treatment with glucokinase activator TTP399 reduced HbA1c in patients with type 1 diabetes

Findings from the Simplici-T1 trial (NCT03335371) suggest that adding the novel hepatoselective glucokinase activator TTP399 to insulin reduced HbA1c by 0.32% at 12 weeks in type 1 diabetics compared with placebo + insulin. The Simplici-T1 study was the first to evaluate the activation of glucokinase in patients with type 1 diabetes receiving a daily oral dose of TTP399 as an adjunct to insulin therapy [1]. The primary endpoint of the randomised, double-blind study was a change in HbA1c at week 12. This study was conducted in 2 parts under the same protocol to evaluate the safety and efficacy of TTP399 in adults with type 1 diabetes. After several weeks of insulin optimisation and placebo run-in, daily dosing with TTP399 was continued for 12 weeks. The 19 patients in part 1 recei...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 14 December, 202016 December, 2020